Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.64 |
| ▸ | FAAH | O00519 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14519882 | 0.81 | CA2 (0.63) | CA2FAAHTP53CES1 | |
| SCHEMBL11101496 | 0.81 | CA2 (0.63) | CA2FAAHTP53CES1 | |
| SCHEMBL1911477 | 0.81 | CA2 (0.63) | CA2FAAHTP53CES1 | |
| SCHEMBL27050891 | 0.81 | CA2 (0.63) | CA2FAAHTP53CES1 | |
| SCHEMBL4005014 | 0.80 | — | — | |
| SCHEMBL34463419 | 0.80 | CA2 (0.57) | CA2FAAHTP53OPRM1CES1 | |
| SCHEMBL7740349 | 0.80 | CA2 (0.57) | CA2FAAHTP53OPRM1CES1 | |
| SCHEMBL5505478 | 0.78 | CA2 (0.59) | CA2FAAHTP53CES1 | |
| SCHEMBL13623537 | 0.78 | CA2 (0.59) | CA2FAAHCES1 | |
| SCHEMBL10707328 | 0.78 | CA2 (0.59) | CA2FAAHCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730836-B2 | Forms of apremilast | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2020-08-04 | — | — | US | disclosed |
| US-20190106389-A1 | NOVEL FORMS OF APREMILAST | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2019-04-11 | — | — | US | disclosed |
| US-10196355-B2 | Forms of apremilast | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2019-02-05 | — | — | US | disclosed |
| US-20170362175-A1 | NOVEL FORMS OF APREMILAST | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-12-21 | — | — | US | disclosed |
| US-9351957-B2 | Amorphous form of apremilast | CADILA HEALTHCARE LIMITED (IN) | 2016-05-31 | — | — | US | disclosed |
| US-20150283249-A1 | AMORPHOUS FORM OF APREMILAST | CADILA HEALTHCARE LIMITED (IN) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730836-B2 | Forms of apremilast | ACE, QDPR, APRT | CA2 2076/4885FAAH 1771/4885TP53 4082/4885 |
| US-20150283249-A1 | AMORPHOUS FORM OF APREMILAST | APRT, MAPT, TNF | CA2 1113/4885FAAH 554/4885TP53 2093/4885 |
| US-20170362175-A1 | NOVEL FORMS OF APREMILAST | MAST4, ACE, APRT | CA2 2701/4885FAAH 1916/4885TP53 4449/4885 |
| US-20190106389-A1 | NOVEL FORMS OF APREMILAST | MAST4, ACE, APRT | CA2 2701/4885FAAH 1916/4885TP53 4449/4885 |
| US-10196355-B2 | Forms of apremilast | ACE, QDPR, APRT | CA2 2076/4885FAAH 1771/4885TP53 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.